MST1 and cancer: These include monoclonal antibodies that neutralize HGFL-dependent Ron signaling [56-60], small molecule inhibitors targeting Ron [61], and the use of anti-Ron antibodies for the delivery of cytotoxic drugs in Ron-overexpressing cancers [62].